Display options
Share it on

Curr Treat Options Cardiovasc Med. 2010 Jan;12(1):76-83. doi: 10.1007/s11936-009-0057-x.

Drug-eluting stents in the elderly.

Current treatment options in cardiovascular medicine

Samip Vasaiwala, Daniel E Forman, Laura Mauri

Affiliations

  1. Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA.

PMID: 20842483 DOI: 10.1007/s11936-009-0057-x

Abstract

OPINION STATEMENT: The introduction of drug-eluting stents (DES) in 2003 has had a great impact on the management of coronary artery disease in the United States. The application of DES to older adults, the population with the highest prevalence of and worst prognosis for coronary artery disease, remains relatively more controversial. Dual-antiplatelet therapy, which is recommended for at least 12 months after DES placement, is particularly problematic for older patients because of greater age-related bleeding risks. Unfortunately, few current data are available to gauge the balance of risk and benefit in elderly community-dwelling DES patients. Although trial data show a benefit for DES among elderly patients, many older adults typically are excluded from randomized trials because of comorbidities, making generalizability of DES safety based on trial data less certain. New, more potent thienopyridines may place the elderly at a particularly elevated bleeding risk. There is a fine balance between efficacy and safety for older DES patients that still needs to be clarified. As the population ages, these issues become more pervasive and of widespread concern. This review summarizes the current literature on DES therapy in the elderly, with a focus on effectiveness and safety profiles of DES versus bare metal stents.

References

  1. Stroke. 2006 Aug;37(8):1969-74 - PubMed
  2. N Engl J Med. 2003 Oct 2;349(14):1315-23 - PubMed
  3. Circulation. 2009 Mar 31;119(12):1682-8 - PubMed
  4. J Am Coll Cardiol. 2005 Oct 18;46(8):1479-87 - PubMed
  5. Pharmacotherapy. 2007 May;27(5):691-6 - PubMed
  6. Am Heart J. 2005 Mar;149(3):474-81 - PubMed
  7. Circ Cardiovasc Interv. 2009 Jun;2(3):178-87 - PubMed
  8. Circulation. 2003 Jan 7;107(1):38-42 - PubMed
  9. J Am Coll Cardiol. 2008 May 27;51(21):2017-24 - PubMed
  10. JAMA. 2005 Sep 14;294(10):1215-23 - PubMed
  11. Circulation. 2007 May 15;115(19):2570-89 - PubMed
  12. N Engl J Med. 2004 Jan 15;350(3):221-31 - PubMed
  13. Circ Cardiovasc Interv. 2009 Feb;2(1):20-6 - PubMed
  14. Am Heart J. 2006 Aug;152(2):321-6 - PubMed
  15. JAMA. 2006 Oct 18;296(15):1858-66 - PubMed
  16. N Engl J Med. 2009 Sep 10;361(11):1045-57 - PubMed
  17. Thromb Res. 2007;121(3):347-52 - PubMed
  18. Lancet. 2003 Jun 14;361(9374):2005-16 - PubMed
  19. Circulation. 2003 Aug 19;108(7):788-94 - PubMed
  20. Circulation. 2005 Oct 4;112(14):2175-83 - PubMed
  21. Eur Heart J. 2007 Mar;28(6):726-32 - PubMed
  22. Circulation. 2007 May 15;115(19):2549-69 - PubMed
  23. N Engl J Med. 2007 Nov 15;357(20):2001-15 - PubMed
  24. Circulation. 2006 Aug 22;114(8):798-806 - PubMed
  25. EuroIntervention. 2005 Aug;1(2):157-64 - PubMed
  26. JACC Cardiovasc Interv. 2009 Mar;2(3):231-9 - PubMed
  27. MMWR Morb Mortal Wkly Rep. 2003 Feb 14;52(6):101-4, 106 - PubMed
  28. J Am Coll Cardiol. 2007 Aug 14;50(7):e1-e157 - PubMed
  29. Am Heart J. 2005 Jan;149(1):67-73 - PubMed
  30. J Invasive Cardiol. 2006 Apr;18(4):162-4 - PubMed
  31. Circulation. 2009 Feb 24;119(7):952-61 - PubMed
  32. Circulation. 2004 Jul 20;110(3):259-64 - PubMed

Publication Types